

Bibliography

1. Peterson, JW, Bo, L, Mork, S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. *Ann Neurol*. 2001; 50(3): 389–400.
2. Geurts, JJ, Barkhof, F. Grey matter pathology in multiple sclerosis. *Lancet Neurol*. 2008; 7(9): 841–851.
3. Kidd, D, Barkhof, F, McConnell, R, et al. Cortical lesions in multiple sclerosis. *Brain*. 1999; 122(1): 17–26.
4. Howell, OW, Reeves, CA, Nicholas, R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. *Brain*. 2011; 134(9): 2755–2771.
5. Magliozzi, R, Howell, O, Vora, A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain*. 2007; 130(4): 1089–1104.
6. Magliozzi, R, Howell, OW, Reeves, C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. *Ann Neurol*. 2010; 68(4): 477–493.
7. Lisak, RP, Benjamins, JA, Nedelkoska, L, et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. *J Neuroimmunol*. 2012; 246(1-2): 85–95.
8. Gardner, C, Magliozzi, R, Durrenberger, PF, et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. *Brain*. 2013; 136(12): 3596–3608.
9. Kooi, EJ, Geurts, JJ, van Horssen, J, et al. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. *J Neuropathol Exp Neurol*. 2009; 68(9): 1021–1028.
10. Torkildsen, O, Stansberg, C, Angelskar, SM, et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. *Brain Pathol*. 2010; 20(4): 720–729.
11. Nielsen, AS, Kinkel, RP, Tinelli, E, et al. Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. *J Magn Reson Imaging*. 2012; 35(3): 537–542.
12. Harrison, DM, Roy, S, Oh, J, et al. Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. *JAMA Neurol*. 2015; 72(9): 1004–1012.
13. Nielsen, AS, Kinkel, RP, Madigan, N, et al. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. *Neurology*. 2013; 81(7): 641–649.
14. Beck, ES, Sati, P, Sethi, V, et al. Improved visualization of cortical lesions in multiple sclerosis using 7T MP2RAGE. *AJNR Am J Neuroradiol*. 2018; 39(3): 459–466.

15. Absinta, M, Vuolo, L, Rao, A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. *Neurology*. 2015; 85(1): 18–28.
16. Harrison, DM, Wang, KY, Fiol, J, et al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. *J Neuroimaging*. 2017; 27(5): 461–468.
17. Zivadinov, R, Ramasamy, DP, Vaneckova, M, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. *Mult Scler*. 2017; 23(10): 1336–1345.
18. Makshakov, G, Magonov, E, Totolyan, N, et al. Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis. *Neurol Res Int*. 2017; 2017: 8652463.
19. Polman, CH, Reingold, SC, Banwell, B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011; 69(2): 292–302.
20. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). *Neurology*. 1983; 33(11): 1444–1452.
21. Jonas, SN, Izbudak, I, Frazier, AA, et al. Longitudinal persistence of meningeal enhancement on postcontrast 7T 3D-FLAIR MRI in multiple sclerosis. *AJNR Am J Neuroradiol*. 2018; 39(10): 1799–1805.
22. Marques, JP, Kober, T, Krueger, G, et al. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. *Neuroimage*. 2010; 49(2): 1271–1281.
23. Tustison, NJ, Avants, BB, Cook, PA, et al. N4ITK: Improved N3 bias correction. *IEEE Trans Med Imaging*. 2010; 29(6): 1310–1320.
24. Bazin, PL, Weiss, M, Dinse, J, et al. A computational framework for ultra-high resolution cortical segmentation at 7Tesla. *Neuroimage*. 2014; 93(2): 201–209.
25. Shiee, N, Bazin, PL, Ozturk, A, et al. A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. *Neuroimage*. 2010; 49(2): 1524–1535.
26. Rothman, KJ. No adjustments are needed for multiple comparisons. *Epidemiology*. 1990; 1(1): 43–46.
27. Schmierer, K, Parkes, HG, So, PW, et al. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. *Brain*. 2010; 133(3): 858–867.
28. Cohen-Adad, J, Benner, T, Greve, D, et al. In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: A surface-based analysis. *Neuroimage*. 2011; 57(1): 55–62.

29. Castellaro, M, Magliozzi, R, Palombit, A, et al. Heterogeneity of cortical lesion susceptibility mapping in multiple sclerosis. *AJNR Am J Neuroradiol.* 2017; 38(6): 1087–1095.
30. Suthiphosuwan, S, Hsu, CC, Bharatha, A. HARMless: Transient cortical and sulcal hyperintensity on gadolinium-enhanced FLAIR after elective endovascular coiling of intracranial aneurysms. *AJNR Am J Neuroradiol.* 2018; 39(4): 720–726.
31. Latour, LL, Kang, DW, Ezzeddine, MA, et al. Early blood-brain barrier disruption in human focal brain ischemia. *Ann Neurol.* 2004; 56(4): 468–477.
32. Chiara Ricciardi, M, Bokkers, RP, Butman, JA, et al. Trauma-specific brain abnormalities in suspected mild traumatic brain injury patients identified in the first 48 hours after injury: A blinded magnetic resonance imaging comparative study including suspected acute minor stroke patients. *J Neurotrauma.* 2017; 34(1): 23–30.
33. Absinta, M, Ha, SK, Nair, G, et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. *Elife.* 2017; 6: e29738.
34. Bevan, RJ, Evans, R, Griffiths, L, et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. *Ann Neurol.* 2018; 84(6): 829–842.
35. Choi, SR, Howell, OW, Carassiti, D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. *Brain.* 2012; 135(10): 2925–2937.
36. Papadopoulos, D, Dukes, S, Patel, R, et al. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. *Brain Pathol.* 2009; 19(2): 238–253.
37. Dragunow, M. Meningeal and choroid plexus cells: Novel drug targets for CNS disorders. *Brain Res.* 2013; 1501: 32–55.
38. Kyran, EL, Robinson, C, Kocovski, P, et al. Multiple pathological mechanisms contribute to hippocampal damage in the experimental autoimmune encephalomyelitis model of multiple sclerosis. *Neuroreport.* 2018; 29(1): 19–24.
39. Magliozzi, R, Howell, OW, Nicholas, R, et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. *Ann Neurol.* 2018; 83(4): 739–755.